`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`___________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`___________
`
`
`MYLAN PHARMACEUTICALS INC.,
`SAWAI USA, INC., AND
`SAWAI PHARMACEUTICAL CO., LTD.,
`Petitioner,
`
`
`v.
`
`
`BIOGEN MA INC.,
`Patent Owner.
`____________________________________________
`
`IPR2018-014031
`Patent No. 8,399,514
`____________________________________________
`
`
`PATENT OWNER’S OBJECTIONS TO
`PETITIONER’S DEMONSTRATIVES
`
`
`
`
`
`
`
`
`
`
`
`
`
`1 Case IPR2019-00789 has been joined with this proceeding.
`
`
`
`U.S. Patent No. 8,399,514
`IPR2018-01403
`
` As authorized by the October 31, 2019, Oral Hearing Order (Paper 76), Patent
`
`Owner objects to Petitioner’s Demonstratives, provided to the Board on November
`
`8, 2019 as follows:
`
` Slide 2: Contains improper new arguments not made in and new evidence
`not cited in Mylan’s pleadings, in particular the arguments relying on Exs.
`1117, 1118, and 1020.
`
` Slide 3: Contains improper new arguments not made in and new evidence
`not cited in Mylan’s pleadings, in particular the arguments relying on Ex.
`1118.
`
` Slide 4: Contains improper new arguments not made in and new evidence
`not cited in Mylan’s pleadings, in particular the arguments relying on Exs.
`1117, 1118, and 1046.
`
` Slide 5: Contains improper new arguments not made in and new evidence
`not cited in Mylan’s pleadings, in particular the arguments relying on Ex.
`1118.
`
` Slide 13: Contains improper new arguments not made in and new evidence
`not cited in Mylan’s pleadings, in particular the arguments relying on Ex.
`1117.
`
` Slide 14: Contains improper new arguments not made in and new evidence
`not cited in Mylan’s pleadings, in particular the arguments relying on Ex.
`1118.
`
` Slide 17: Contains improper new arguments not made in Mylan’s pleadings,
`in particular the arguments relying on Ex. 1015.
`
` Slide 21: Contains improper new arguments not made in Mylan’s pleadings,
`in particular the arguments related to “Annualized Relapse Rate.”
`
` Slide 30: Contains improper new arguments not made in and new evidence
`not cited in Mylan’s pleadings, in particular the arguments relying on Ex.
`
`1
`
`
`
`U.S. Patent No. 8,399,514
`IPR2018-01403
`
`1019 regarding the active ingredients of Fumaderm® and arguments relying
`on Exs. 1021 and 1027.
`
` Slide 33: Contains improper new arguments not made in Mylan’s pleadings,
`in particular the arguments regarding relying on Exs. 1014 and 1019.
`
` Slide 35: Contains improper new arguments not made in and new evidence
`not cited in Mylan’s pleadings, in particular the arguments relying on Ex.
`1118.
`
` Slide 40: Contains improper new arguments not made in and new evidence
`not cited in Mylan’s pleadings, in particular the arguments relying on Ex.
`1066.
`
` Slide 42: Contains improper new arguments not made in Mylan’s pleadings,
`in particular the argument “Confirmation by Kappos 2008” relying on Ex.
`1048, 8.
`
` Slide 43: Contains improper new arguments not made in and new evidence
`not cited in Mylan’s pleadings, in particular the arguments relying on Ex.
`1047.
`
`
`Dated: November 8, 2019
`
`
`
`
`
`
`
`By: /Barbara C. McCurdy/
`
`Barbara C. McCurdy, Reg. No. 32,120
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`
`Counsel for Patent Owner
`Biogen MA Inc.
`
`2
`
`
`
`U.S. Patent No. 8,399,514
`IPR2018-01403
`
`
`CERTIFICATE OF SERVICE
`
`
`
`The undersigned certifies that a copy of the foregoing PATENT OWNER’S
`
`OBJECTIONS TO PETITIONER’S DEMONSTRATIVES were served
`
`electronically via email on November 8, 2019, in their entirety, on the following:
`
`Brandon M. White
`Shannon M. Bloodworth
`Michael A. Chajon
`Maria A. Stubbings
`Nathan Kelley
`Perkins Coie LLP
`700 13th St., NW, Suite 600
`Washington, D.C. 20005
`Telephone: (202) 654-6206
`Email: bmwhite@perkinscoie.com
`Email: sbloodworth@perkinscoie.com
`Email: mchajon@perkinscoie.com
`Email: mstubbings@perkinscoie.com
`Email: nkelley@perkinscoie.com
`
`David L. Anstaett
`Emily J. Greb
`Perkins Coie LLP
`One East Main St., Suite 201
`Madison, WI 53703
`Telephone: (608) 663-7494
`Email: danstaett@perkinscoie.com
`Email: egreb@perkinscoie.com
`
`Courtney M. Prochnow
`Perkins Coie LLP
`633 W. 5th St., Suite 5850
`Los Angeles, CA 90071
`Telephone: (310) 788-3284
`Email: cprochnow@perkinscoie.com
`
`
`
`
`
`U.S. Patent No. 8,399,514
`IPR2018-01403
`
`Brian Sodikoff
`Martin S. Masar III, Ph.D.
`Katten Muchin Rosenman LLP
`525 West Monroe Street
`Chicago, IL 60661-3693
`Telephone: (312) 902-5462
`Email: brian.sodikoff@kattenlaw.com
`Email: martin.masar@kattenlaw.com
`
`Christopher B. Ferenc
`Katten Muchin Rosenman LLP
`2900 K Street NW,
`North Tower - Suite 200
`Washington, DC 20007
`Telephone: (202) 625-3647
`Email: Christopher.ferenc@kattenlaw.com
`
`
`By: /Barbara C. McCurdy/
`Barbara C. McCurdy, Reg. No. 32,120
`
`
`Petitioner has agreed to electronic service.
`
`
`Dated: November 8, 2019
`
`
`
`
`
`
`
`